RecruitingNot Applicable

Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia

Italy510 participantsStarted 2021-02-06

Plain-language summary

Prospective, multicenter, national, observational pharmacological study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis (EF) bloodstream infection (BSI) and identification of gut microbiota fingerprint of patients with EF-BSI correlated to antimicrobial treatment and clinical outcome

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult (≥18 years) * Monomicrobial EF-BSI * Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy * Written informed consent Exclusion Criteria: * Short term (within 3 days from BSI) mortality * Other concomitant infection

What they're measuring

Evaluation of Clinical Cure and Improvement Rates for EF-BSI

Timeframe: Up to 6 weeks from patient enrollment, with bacterial strains isolated at baseline

Comparison of Clinical Outcomes Between Mono Therapy and Combination Therapy

Timeframe: Up to 6 weeks from patient enrollment, with bacterial strains isolated at baseline

Validation of In Vitro Synergy Tests

Timeframe: Up to 6 weeks from patient enrollment, with bacterial strains isolated at baseline

Trial details

NCT IDNCT06833593

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-09-26

Contact for this trial

Maddalena Giannella, MD PhD

+39 0512143199 maddalena.giannella@unibo.it

View on ClinicalTrials.gov More Enterococcus Faecalis Infection trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Evaluation of Clinical Cure and Improvement Rates for EF-BSI

Timeframe: Up to 6 weeks from patient enrollment, with bacterial strains isolated at baseline

Comparison of Clinical Outcomes Between Mono Therapy and Combination Therapy

Timeframe: Up to 6 weeks from patient enrollment, with bacterial strains isolated at baseline

Validation of In Vitro Synergy Tests

Timeframe: Up to 6 weeks from patient enrollment, with bacterial strains isolated at baseline